<DOC>
	<DOC>NCT02635724</DOC>
	<brief_summary>This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications. All subjects will receive IV peramivir.</brief_summary>
	<brief_title>Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Peramivir</mesh_term>
	<criteria>A positive influenza Rapid Antigen Test (RAT) and/or a FDAapproved PCR test and at least one clinical sign or symptom consistent with acute influenza infection as listed below OR Clinical signs and symptoms consistent with acute influenza infection consisting of an oral temperature ≥ 100°F (37.8°C) with at least one respiratory symptom of at least moderate severity (cough or rhinitis) and at least one constitutional symptom of at least moderate severity (myalgia [aches and pains], headache, feverishness, or fatigue) Influenza symptom onset &lt; 48 hours Pregnant females Subjects requiring hospital admission Recent worsening of any chronic medical condition consistent with complications of influenza Current evidence of a bacterial infection requiring antibiotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute uncomplicated</keyword>
	<keyword>Elderly</keyword>
</DOC>